18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy

Gaurav Malviya1†, Rachana Patel1†, Mark Salji1,2,3, Rafael S. Martinez1,2, Peter Repiscak1, Ernest Mui1,2, Susan Champion4, Agata Mrowinska1, Emma Johnson1, Maha AlRasheedi2, Sally Pimlott4, David Lewis1,2* and Hing Y. Leung1,2,3*

Abstract

**Background:** Prostate cancer is highly prevalent worldwide. Androgen deprivation therapy (ADT) remains the treatment of choice for incurable prostate cancer, but majority of patients develop disease recurrence following ADT. There is therefore an urgent need for early detection of treatment resistance.

**Methods:** Isogenic androgen-responsive (CWR22Res) and castration-resistant (22Rv1) human prostate cancer cells were implanted into the anterior lobes of the prostate in CD-1 Nu mice to generate prostate orthografts. Castrated mice bearing CWR22Res and 22Rv1 orthografts mimic clinical prostate cancer following acute and chronic ADT, respectively. 18F-Fluciclovine (1-amino-3-fluorocyclobutane-1-carboxylic acid) with a radiochemical purity of > 99% was produced on a FASTlab synthesiser. Ki67 staining in endpoint orthografts was studied. Western blot, quantitative RT-PCR and next-generation sequencing transcriptomic analyses were performed to assess the expression levels of amino acid transporters (including LAT1 and ASCT2, which have been implicated for Fluciclovine uptake). Longitudinal metabolic imaging with 18F-Fluciclovine-based positron emission tomography (PET) was performed to study tumour response following acute and chronic ADT.

**Results:** Both immunohistochemistry analysis of endpoint prostate tumours and longitudinal 18F-Fluciclovine imaging revealed tumour heterogeneity, particularly following ADT, with in vivo 18F-Fluciclovine uptake correlating to viable cancer cells in both androgen-proficient and castrated environment. Highlighting tumour subpopulation following ADT, both SUVpeak and coefficient of variation (CoV) values of 18F-Fluciclovine uptake are consistent with tumour heterogeneity revealed by immunohistochemistry. We studied the expression of amino acid transporters (AATs) for 18F-Fluciclovine, namely LAT1 (SLC7A5 and SLC3A2) and ASCT2 (SLC1A5). SLC7A5 and SLC3A2 were expressed at relatively high levels in 22Rv1 castration-resistant orthografts following chronic ADT (modelling clinical castration-resistant disease), while SLC1A5 was preferentially expression in CWR22Res tumours following acute ADT. Additional

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

*Correspondence: d.lewis@beatson.gla.ac.uk; h.leung@beatson.gla.ac.uk
†Gaurav Malviya and Rachana Patel have equal contribution
‡Rachana Patel and Gaurav Malviya: Joint first authors
1 Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK
Full list of author information is available at the end of the article
AATs such as SLC43A2 (LAT4) were shown to be upregulated following chronic ADT by transcriptomic analysis; their role in Fluciclovine uptake warrants investigation.

**Conclusion:** We studied in vivo $^{18}$F-Fluciclovine uptake in human prostate cancer orthograft models following acute and chronic ADT. $^{18}$F-Fluciclovine uptakes highlight tumour heterogeneity that may explain castration resistance and can be exploited as a clinical biomarker.

**Keyword:** Castration-resistant prostate cancer, Metabolic imaging, $^{18}$F-Fluciclovine (FACBC), Amino acid transporter, Tumour heterogeneity

---

**Introduction**

Prostate cancer is a leading cause of premature male cancer-related death [1]. Despite the common practice of testing for serum prostate-specific antigen (PSA) levels in asymptomatic men, a significant proportion of patients present with advanced and/or metastatic disease. While androgen deprivation therapy (ADT) with analogue or antagonist of luteinising hormone-releasing hormone is the standard of care systemic treatment for incurable disease, increasingly docetaxel chemotherapy or additional inhibitor of the androgen receptor pathway is used in combination with standard of care ADT [2–4]. Following ADT, the majority of patients will show an initial favourable response with a dramatic fall in serum PSA levels, but will subsequently develop cancer recurrence, which is referred to as castration-resistant prostate cancer (CRPC), and remains incurable.

Metabolic imaging such as positron emission tomography (PET) has the potential to detect occult and/or persistent disease following treatment. The personalised information obtained can guide management decisions as well as support the design of future trials focussing on prostate cancer patients with the earliest signs of tumour resistance to ADT, prior to clinical evidence of cancer recurrence judged by PSA testing. Active transport of synthetic L-leucine analogues such as $^{18}$F labelled 1-amino-3-fluorocyclobutane-1-carboxylic acid (or $^{18}$F-Fluciclovine or $^{18}$F-FACBC) into cells is thought to be mediated by L-type neutral amino acid transporter 1 (LAT1) and alanine-serine-cysteine-transporter (ASCT2) [5, 6]. LAT1 is a sodium independent exchange amino acid transporter (AAT) between intracellular and extracellular environments [7]. In contrast, ASCT2 mediates amino acid uptake in a sodium-dependent manner [7, 8]. As a leucine analogue, $^{18}$F-Fluciclovine is not incorporated into proteins, but its uptake mirrors that of glutamine [6, 9], which plays a key role in cancer metabolism [7]. As both LAT1 and ASCT2 have been detected in prostate cancer cells, $^{18}$F-Fluciclovine is a promising PET radiotracer for functional prostate cancer imaging. $^{18}$F-Fluciclovine is already approved by the European Medicines Agency in Europe [10] and the Food and Drug Administration in the USA [11] for diagnostic imaging in prostate cancer sufferers with biochemical evidence of cancer recurrence. Favourable cancer detection performance for $^{18}$F-Fluciclovine PET imaging has been reported across a wide range of PSA values [12, 13].

Androgen receptor contributes to prostate carcinogenesis and treatment resistance through its effects on cancer metabolism. To date, studies on castration-resistant prostate cancer have primarily focussed on in vitro cell models. Here, we developed the CWR22Res and 22Rv1 isogenic human prostate orthografts (orthotopic xenografts) as models of androgen-responsive (dependent) and castration-resistant prostate cancer. We hypothesise that castration-resistant prostate cancer has a distinct profile of AATs expression that alters the tumoral $^{18}$F-Fluciclovine uptake. We applied acute and chronic ADT (in CWR22Res and 22Rv1 orthografts, respectively) as tools to mimic early and established castration-resistant disease and performed longitudinal (matched) $^{18}$F-Fluciclovine PET/MRI scans.

**Material and methods**

**In vivo model of human prostate cancer orthografts**

Isogenic androgen-responsive CWR22Res and castration-resistant 22Rv1 human prostate cancer cells were implanted into the anterior lobes of the prostate in CD-1 Nu mice to generate prostate orthografts ($n=4$ for CWR22Res and $n=3$ for 22Rv1) as described in Patel et al.[14].

Mice bearing CWR22Res orthografts maintained in an androgen-proficient state (i.e. without castration) are referred to as hormone-naïve tumours. Two experimental groups were designed to recapitulate clinical acute ADT and chronic ADT. For acute ADT, mice bearing CWR22Res orthografts were castrated, and PET/MRI scans were performed before and after ADT (Fig. 1a top). For chronic ADT, castration-resistant 22Rv1 cells were orthotopically implanted and the mice castrated at the same time. Tumour formation was confirmed by ultrasonography, followed by two serial PET/MRI scans (Fig. 1a bottom). The effect of ADT was anticipated within three weeks, so for both acute (CWR22Res) and chronic (22Rv1) ADT treatment groups, the interval between PET/MRI scan 1 and scan 2 was 21 days.
Mice were anaesthetised using isoflurane during imaging procedures. Experiments involving the use of mice were conducted in accordance with the UK Home Office regulations (UK Animals (Scientific Procedures) Act 1986) under the Project Licence P5E22AEE.

Sections from orthografts were prepared and analysed by haematoxylin and eosin staining as well as by immunohistochemistry for the levels of Ki67 (a marker for cell proliferation) as described in Patel et al. [14].

**18F-Fluciclovine synthesis**

18F-Fluciclovine was produced on a FASTLab synthesiser, using single use cassette kits provided by Blue Earth Diagnostics Limited. The 18F-Fluciclovine (or 18F- FACBC) was produced with a radioactivity yield of 49.1 ± 3.8% (n = 4) and the end of synthesis activity concentration of 1481 ± 190 MBq/ml. At end of synthesis the radiochemical purity was found to be 99.18 ± 0.13% (n = 4, Additional file 1: Figure S1), and the molar activity was found to be 1044.45 ± 638.14 GBq/µmol (n = 3). The final 18F-Fluciclovine product was formulated in citrate buffer and was terminally filtered through a 0.2-µm filter.

Radiochemical purity was measured using thin-layer chromatography. Thin-layer chromatography silica gel 60 aluminium sheets strips were eluted over 7.5 cm using a mobile phase consisting of acetonitrile:methanol:water:acetic acid at 20:5:5:1 v/v.

**18F-Fluciclovine PET/MRI imaging**

18F-Fluciclovine positron emission tomography/magnetic resonance imaging (PET/MRI) scans on mice bearing prostate orthografts were performed using a nanoScan PET/MRI scanner (Mediso Medical Imaging Systems, Hungary). Mice were maintained under inhaled isoflurane anaesthesia (induction 5% v/v; maintenance 1.5–2.0% v/v) in the medical air during injection and PET/MRI imaging procedures periods. Each mouse received 15.9 ± 4.6 MBq of 18F-Fluciclovine radiotracer via an intravenous bolus injection in tail vein. Static PET acquisitions were performed for 15 min after an uptake period of 50 min. Whole-body T1-weighted Gradient Echo 3D Coronal/Sagittal MRI Sequences (slice thickness 0.5 mm, repetition time 12.057 ms, echo time 3.3 ms, flip angle 15 degrees) were used to acquire MRI scans.

Image reconstruction was performed using 3D TeraTomo software (Mediso Medical Imaging Systems, Hungary), and PET data were corrected for radioactivity decay, random coincidences, scatter, attenuation and dead time. The reconstructed PET scans were co-registered with MRI scans for anatomical reference.

For quantitative assessments of scans, volume-of-interest (VOI) was manually drawn around the prostate on MRI scans by visual inspection using PMOD software version 3.504 (PMOD Technologies Ltd., Switzerland), and same VOI copied on to the respective PET scans. Separate VOIs were drawn for each scan to adjust for the position of the mice on the scanner and tumour size. Standardised uptake values (SUV) were determined by dividing the radiotracer concentration in VOI by the injected dose divided by the animal weight. SUVmean values were calculated using mean of all pixel values within tumour VOI. SUVmax values were derived from the hottest VOI pixel values, while SUVpeak values were calculated using mean of five hottest VOI pixel values. Coefficient of variation (CoV) was determined by dividing the standard deviation by the mean 18F-Fluciclovine uptake. Data were analysed using a 2-way ANOVA followed by post hoc Sidak's multiple comparison tests in the GraphPad Prism software version 8.4.3 (GraphPad software LLC, USA).

**Western blot analysis**

Cell lysates from prostate orthografts were prepared as previously described in Patel et al. [15] and Rushworth et al. [16]. Lysates were resolved by SDS-PAGE in 4–12% gradient Bis–Tris gels (Life Technologies) before wet transfer to PVDF membrane (Millipore) using the NuPage transfer module (Life Technologies). Membranes were blocked with 5% milk before incubation with primary antibody overnight at 4 °C, with anti-SLC7a5 antibody from Cell Signalling (5347S), anti-SLC3a2 antibody from Sigma-Aldrich (SAB1400263), anti-SLC1a5...
antibody from Invitrogen (PA5-50,527) and anti-HSC70 antibody from Santa Cruz (sc-7298). Following incubation with secondary antibodies, using Alexa Fluor 680 goat anti-rabbit (Life Technologies) or goat anti-mouse DyLight 800 (ThermoFisher Scientific), western blot membranes were scanned using the LI-COR Odyssey.
CLx Imaging system (LI-COR Biosciences) and visualised with the Image Studio Lite Ver 5.2 software.

Transcriptomic analysis of castration-resistant prostate cancer orthografts
mRNA was extracted from orthografts using RLT buffer supplemented with 1% β-mercaptoethanol according to the manufacturer’s instructions for the RNeasy Mini Kit (Qiagen). RNA was quantified using the NanoDrop 2000 spectrophotometer (Thermo Scientific). For RNA sequencing samples, RNA quality was assessed on a 2100 Bioanalyser (Agilent). Libraries from RNA samples were prepared for sequencing using the Illumina TotalPrep RNA Amplification Kit (Ambion, Life Technologies) with cytoplasmic and mitochondrial ribo-depletion (Illumina Ribo-Zero Gold Stranded Kit) according to the manufacturer’s instructions. Quality checks and trimming of the raw RNA-Seq data files were conducted using FastQC (v0.11.8), Trim Galore (v0.6.4) and FastQ Screen (v0.13.0). RNA-Seq paired-end reads were aligned to the human genome (GRCh38 v95) using HiSat2 (v2.1.0), and gene expression levels were determined using featureCounts (v1.6.4). Differential gene expression analysis, based on the negative binomial distribution, was performed using DESeq2 package (v1.26.0), and expression of significantly (p-adj < 0.05) differentially expressed amino acid transporters was plotted as a heatmap using pheatmap (v1.0.12). Analysis was performed in the R environment (v3.6.3).

Results
CWR22Res and 22Rv1 orthograft models mimic clinical hormone-dependent and castration-resistant prostate cancer
CWR22Res (hormone-dependent) and 22Rv1 (castration-resistant) human isogenic prostate cancer cells were implanted orthotopically in immune-compromised nude mice to generate orthografts. The experimental plan as outlined in Fig. 1a was designed to support longitudinal imaging analyses of in vivo tumour growth following both acute and chronic ADT in mice bearing CWR22Res and 22Rv1 orthografts, respectively.

Based on MRI imaging performed at the same time as PET, we calculated the orthograft size in each mouse at two time points 21 days apart (Fig. 1b). CWR22Res tumours continued to increase in size (p = 0.01, paired t test) after acute ADT (by castration). In contrast, we only observed a marginal increase in 22Rv1 tumour size (p = 0.06, paired t test), after chronic ADT (by castration), as often observed in clinical castration-resistant tumours.

We analysed the orthografts by haematoxylin and eosin staining as well as by immunohistochemistry for the levels of Ki67 (a marker for cell proliferation) (Fig. 1c). We observed areas of viable tumour positive for Ki67 expression and patchy areas of necrotic tissue stained negative for Ki67. Comparing CWR22Res orthografts before and after castration, the level of necrosis appeared higher following castration.

18F-Fluciclovine PET/MRI imaging
We performed longitudinal PET/MRI metabolic imaging on prostate orthograft bearing mice at two time points to monitor changes in 18F-Fluciclovine uptake following acute and chronic ADT, respectively. Mice bearing CWR22Res orthografts underwent 18F-Fluciclovine PET/MRI imaging prior to castration, and a follow-up PET/MRI performed at 21 days later, mimicking acute ADT. Similarly, once 22Rv1 castration-resistant prostate orthografts were confirmed in a castrated environment by ultrasonography, a 18F-Fluciclovine PET/MRI scan was performed, with a follow-up scan at 21 days later, recapitulating clinical chronic ADT.

Analysis of matched SUVmean values for CWR22Res orthografts before and after acute ADT identified a significant reduction in SUVmean (p-adj = 0.0002; two-way ANOVA), signifying a global reduction of tumoral 18F-Fluciclovine uptake following castration (Fig. 2a, b, 3a). In contrast, the castration-resistant 22Rv1 orthografts maintained SUVmean values between the two scans (p-adj = 0.1428; two-way ANOVA), albeit at relatively low levels (Fig. 2c, d, 3a), suggesting sustained amino acid transporter expression during in vivo CRPC growth under chronic ADT condition. There was consistently less 18F-Fluciclovine uptake in castrate-resistant 22Rv1 tumours compared to hormone-sensitive CWR22Res orthografts (p < 0.0001; two-way ANOVA).

Tumour heterogeneity and plasticity represent an important cellular adaptive response to overcome selective pressure from castration. Consistent with findings from histopathology analysis (Fig. 1c), tumour heterogeneity was evident on PET/MRI imaging (Fig. 2). We therefore carried out comprehensive SUV analyses to include data from SUVmean, SUVpeak, SUVmax and coefficient of variation on PET image data (Fig. 3, Additional file 1: S2). Despite significant change in the SUVmean for CWR22Res orthografts following castration (Fig. 3b), the respective SUVpeak and SUVmax values before and after castration were comparable (Fig. 3c, Additional file 1: S2). For 22Rv1 orthografts, SUVmean, SUVpeak and SUVmax values were all sustained in the longitudinal scans. Consequently, tumour heterogeneity, as measured by the coefficient of variation across the tumour volume, increased in acute ADT (p-adj = 0.0099, two-way ANOVA) but not chronic ADT (p-adj = 0.2513) (Fig. 3c). Collectively, our SUV analyses support the
concept that a tumour subpopulation with sustained \(^{18}\text{F}-\text{Fluciclovine}\) uptake following castration may represent cancer resistant to ADT and may therefore contribute to the development of CRPC.

**Analysis of amino acid transporters (AATs) expression**

\(^{18}\text{F}-\text{Fluciclovine}\) (or \(^{18}\text{F}-\text{FACBC}\)) is a synthetic L-leucine analogue taken up by cells via amino acid transporters (AATs), with the LAT1 and ASCT2 transporters particularly implicated [5]. We assayed the expression levels of relevant amino acid transporters at both protein and mRNA levels. LAT1 consists of a heterodimer from the gene products of \(\text{SLC7A5}\) and \(\text{SLC3A2}\), while ASCT2 is encoded by \(\text{SLC1A5}\). On western blotting, SLC7A5 and SLC3A2 were both upregulated in 22Rv1 orthografts, when compared to CWR22Res orthografts following castration (Fig. 4a). In contrast, 22Rv1 castration-resistant orthografts expressed SLC1A5 at a lower level than the androgen-dependent CWR22Res tumours (Fig. 4a).

We further performed quantitative RT-PCR to assay for mRNA levels of \(\text{SLC1A5}\) (or ASCT2) and \(\text{SLC7A5}\) (part of LAT1) and confirmed reduced ASCT2 and increased LAT1 expression in 22Rv CRPC compared to CWR22Res androgen-dependent tumours (Fig. 4b).

To further explore potential AAT targets for \(^{18}\text{F}-\text{Fluciclovine}\) uptake in our in vivo treatment-resistant prostate...
cancer model, we utilised data from transcriptomic analysis of prostate orthografts [17]. Expression levels of significantly ($p$-adj < 0.05) differentially expressed AAT are presented as a heatmap (Fig. 4c). SLC7A5 and SLC1A5 mRNA expression was consistent with that observed at protein level, i.e. elevated SLC7A5 and reduced SLC1A5 levels in the castration-resistant 22Rv1 tumours.

Besides sustained SLC7A5 (LAT1) mRNA expression, we observed upregulated expression of SLC43A2 and SLC6A7. SLC43A2 (Solute Carrier Family 43 Member 2 or Large Neutral Amino Acids Transporter Small
Subunit 4, LAT4) is the most significantly upregulated AAT (log2FC = 1.78, p-adj = 1.32E-0.9) in 22Rv1 CRPC (Additional file 1: Table S1).

Discussion
Metabolic imaging is increasingly applied in the management of cancer patients, particularly for the detection of occult and/or persistent disease following treatment. The current standard of care imaging with the use of CT, MRI and isotopic bone scan cannot detect small foci of primary and metastatic disease. PET/MRI imaging with 18F-Fluciclovine, a radiolabelled synthetic amino acid, in prostate cancer patients may locate disease recurrence and guide management decision in a personalised manner [18]. Unlike 18F-fluorodeoxyglucose, it is not absorbed by all cells with an increased glucose metabolic rate, but specifically targets cell surface amino acid transporters ASCT2 and LAT1 overexpressed in prostate cancer.

We have optimised a preclinical orthotopic xenograft (orthograft) mouse model of prostate cancer to mimic clinical castration-resistant disease and examined the application of longitudinal 18F-Fluciclovine-based imaging in treatment-resistant prostate cancer. We identified intra-tumoral heterogeneity following androgen deprivation therapy, corroborating data from immunohistochemistry analysis with PET signals. Consistent with the literature adaptive upregulation of LAT1 expression in castration-resistant tumours was observed. In addition, unbiased transcriptomic analysis implicated upregulated SLC43A2 (LAT4) expression as a candidate amino acid transporter associated with resistance to castration.

Majority of patients following androgen deprivation therapy have excellent drop in serum PSA levels. Within the current clinical practice, we are unable to identify patients at high risk of early disease recurrence. Data from longitudinal 18F-Fluciclovine PET imaging revealed intra-tumoral heterogeneity that may explain cancer subpopulation surviving androgen deprivation therapy (castration). These viable tumour cells signify the basis of subsequent recurrent tumour. In the future, 18F-Fluciclovine PET imaging following treatment may help clinicians to identify patients at high risk of early cancer recurrence and therefore provide the opportunity to consider additional treatment, while the bulk of resistant cancer remains low.

Besides 18F-Fluciclovine-based imaging, other PET tracers including [11C]choline and PSMA (prostate-specific membrane antigen)-based tracers have also been investigated following activation or suppression of the androgen receptor [19–21]. Comparing the accuracy of 18F-Fluciclovine and [11C]choline PET imaging in a cohort of 100 patients with biochemical recurrence following previous radical treatment, 18F-Fluciclovine had better true-positive, false-positive, true-negative and false-negative rates (Chi-squared test, p < 0.0001) as well as practical advantage over [11C]choline, including ease of handling and scan interpretation [22]. 11F-Fluciclovine PET also performs favourably in detecting recurrent disease, including nodal metastasis [23] (with pathologic confirmation [24]), when compared to [11C]choline PET.

In a recent head-to-head comparative study in patients with recurrent prostate cancer [20], while 18F-Fluciclovine and [68 Ga]Ga-PSMA-11 PET imaging had similar detection rates (79.3%, 18F-fluciclovine; 82.8%, [68 Ga]Ga-PSMA-11; p = 0.64), 18F-fluciclovine was more efficient in detecting local recurrence in 37.9% of examined cases (compared to 27.6% for [68 Ga]Ga-PSMA-11, p = 0.03). However, additional comparative studies are required to determine the PET tracer of choice to detect CRPC with confidence.

Orthografts generated from CWR22Res and derived 22Rv1 cells represent excellent preclinical models for androgen-dependent and castration-resistant prostate cancer. Importantly, these novel mouse models demonstrated to be relevant to clinical prostate cancer, particularly castration-resistant prostate cancer. Surgical castration has the benefit of instantaneously achieving androgen deprivation, providing a clear time point when effective hormone treatment commences. This contrasts with chemical castration which often takes six weeks to reach optimal effects. Once androgen deprivation therapy is in place, substantial effects on the prostate cancer are expected within two to three weeks. The interval of three weeks between first and second scans ensures that we detect tumour response to castration as well as demonstrate evidence of viable tumour cells that may subsequently develop into recurrence disease.

CWR22Res and 22Rv1 maintain the expression of androgen receptor. We observed generally higher levels of 18F-Fluciclovine uptake in androgen-proficient environment. Nevertheless, in castrated environment, 18F-Fluciclovine ‘hot spots’ help to highlight viable tumour cells following both acute and chronic ADT. We examined the application of longitudinal 18F-Fluciclovine-based imaging in treatment-resistant prostate cancer and identified tumour heterogeneity, which was supported by morphologic findings from immunohistochemistry analysis.

The levels of 18F-Fluciclovine uptake differ in tumours growing in androgen-proficient and castrated conditions. The thresholds and SUV parameters (namely SUVmean, SUVpeak and SUVmax) adopted for clinical 18F-Fluciclovine PET reporting may therefore require appropriate assessment and may vary in different (namely treatment naive or castration resistant) clinical context. Collectively, our data are consistent with the notion that viable
tumour subpopulations (highlighted by SUVpeak, SUVmax and CoV) may be involved in treatment resistance and can be detected by longitudinal $^{18}$F-Fluciclovine imaging. Future prospective studies to follow patients receiving ADT are warranted.

The experimental design of our study enables direct comparison of data obtained from the longitudinal PET/MRI scans. It was not possible to obtain matched tumour materials from the time of the first scan to carry out molecular analyses using methodologies such as immunohistochemistry, western blotting and next-generation sequencing transcriptomic studies. Nonetheless, we were able to confirm upregulated expression of LAT1 following chronic ADT at both protein and mRNA levels, while ASCT2 (SLC1A5) expression was at low level in 22Rv1 CRPC tumours under chronic ADT.

Analysis of amino acid transporter expression in the context of Fluciclovine uptake has been studied using in vitro prostate cancer cell models. ASCT2 (SLC1A5) was shown to correlate with $^{14}$C-Fluciclovine uptake in androgen receptor-positive human LNCaP prostate cancer cells in vitro [25, 26]. In a study looking at the dynamics of ASCT2 across different prostate cancer states, ASCT2 expression appeared to have an overall minor decrease from androgen-sensitive to castration-resistant states, which is consistent with our data [27]. The ‘ying-yang’ pattern of LAT1 expression between androgen-sensitive and castration-resistant states observed in our study fits with what has been previously reported [28]. More recently, consistent with our findings, high levels of LAT1 expression in resected prostate tumours positively and significantly correlated with tumoral $^{18}$F-Fluciclovine uptake [8]. Hence, the in vivo model of CRPC presented here mimics clinical disease and further builds on previously studies based on in vitro models.

Finally, we presented comprehensive transcriptomic analysis of AAT expression in CRPC and identified a number of novel AATs such as LAT4 being upregulated. LAT4 is involved in sodium-, chloride- and pH-independent transport of L-isomers of neutral amino acids such as leucine, phenylalanine, valine and methionine. The role of LAT4 in the development of CRPC and in $^{18}$F-Fluciclovine uptake therefore warrants further investigation.

Conclusion
Persistence of $^{18}$F-Fluciclovine uptake may signify the presence of tumour resistance to ADT, and upregulated tumoral expression of LAT1 following chronic ADT may at least in part mediate $^{18}$F-Fluciclovine uptake. Detecting castration-resistant cancer cells may facilitate patient stratification to receive additional treatment. Future clinical trials can incorporate the use of a post-treatment PET scan to identify patients suitable for adjuvant trial treatment.

Key points
Question
What is the in vivo relationship between androgen deprivation therapy and tumoral uptake of $^{18}$F-Fluciclovine PET tracer in the context of castration-resistant prostate cancer?

Pertinent findings
Using novel isogenic prostate orthografts to model clinical prostate cancer, $^{18}$F-Fluciclovine uptake highlighted tumour heterogeneity and treatment resistance. LAT1 (and not ASCT2) is implicated as a potential AAT for $^{18}$F-Fluciclovine uptake in CRPC, and additional AAT (e.g. SLC43A2/LAT4) is implicated by unbiased transcriptomic analysis.

Implications for patient care
$^{18}$F-Fluciclovine PET imaging may detect CRPC at the earliest stage of tumour resistance.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13550-020-00728-9.

Additional file 1. Supplementary information.

Abbreviations
ADT: Androgen deprivation therapy; MRI: Magnetic resonance imaging; PET: Positron emission tomography; PSA: Prostate-specific antigen; CRPC: Castration-resistant prostate cancer; VOI: Volume-of-interest; SUV: Standardised uptake value; CoV: Coefficient of variation.

Acknowledgements
We thank staff at the PET Radiopharmaceutical Production Unit, NHS Greater Glasgow and Clyde for producing the $^{18}$F-Fluciclovine tracer. We thank Eugene Teoh for helpful comments on the manuscript and Linda Rushworth for assistance with the bibliography. We are also grateful to the CRUK Beatson Institute Central Services, Histology Service and Biological Services Unit for technical support.

Authors’ contributions
GM, RP, MS, DL, HYL designed the study, GM, RP, MS, RSM, EM, SC, AM, EJ, SP conducted experiments, MA, GM, RP, HYL analysed the data, and GM, RP, MA, RP, RSM, DL, HYL lead the manuscript preparation (with support from all co-authors).

Funding
Research funding was provided by Cancer Research UK (C596/A17196—core funding to the CRUK Beatson Institute and A15151, A22904 (awarded to HYL) and A25006 (awarded to DL)).

Availability of data and materials
Relevant data in support of this paper can be requested from the corresponding authors.
Ethical approval and consent to participate
Experiments involving the use of mice were conducted in accordance with the UK Home Office regulations (UK Animals (Scientific Procedures) Act 1986) under the Project Licence P3EE228E.

Consent for publication
All authors have read and approve the submission of the manuscript.

Competing interests
Blue Earth Diagnostics Limited (Oxford, UK) provided the FASTlab cassettes used in the synthesis of the 18F-Fluciclovine tracer. Experimental design and data analysis of the study were independent of Blue Earth Diagnostics Limited. The authors have no additional declarations.

Author details
1 Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK. 2 Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. 3 Department of Urology, NHS Greater Glasgow and Clyde, Glasgow, UK. 4 West of Scotland PET Centre, NHS Greater Glasgow and Clyde, Glasgow, UK.

Received: 18 June 2020   Accepted: 29 October 2020

Published online: 25 November 2020

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
2. Fizazi K, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.
3. James ND, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.
4. James ND, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.
5. Okudaira H, et al. Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. Nucl Med Biol. 2013;40(5):670–5.
6. Okudaira H, et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med. 2011;52(5):822–9.
7. Turk PET Centre https://www.turkpetcentre.net/petanalysis/analysis_18f-fluciclovine.html.
8. Saarinen L, et al. Correlation between (18)F-1-amino-3-fluorocyclobutane-1-carboxylic acid ((18)F-Fluciclovine) uptake and expression of alanineserine-cysteine-transporter 2 (ASC72) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. EJNMMI Res. 2019;9(1):50.
9. Oka S, et al. Transport mechanisms of trans-1-amino-3-fluorocyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol. 2012;39(1):109–19.
10. European Medicines Agency https://www.ema.europa.eu/en/medicines/human/EPAR/axumin.
11. FDA News Release: FDA approves new diagnostic imaging agent to detect recurrent prostate cancer. https://www.fda.gov/news-events/press-announcements/fda-approves-new-diagnostic-imaging-agent-detect-recurrent-prostate-cancer.
12. Odewole OA, et al. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging. 2016;43(10):1773–83.
13. Bach-Gansmo T, et al. Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine ((18)F) positron emission tomography/computed tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017;197(3 Pt 1):676–83.
14. Patel R, et al. Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1. EMBO Mol Med. 2014.
15. Patel R, et al. Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest. 2013;123(3):1157–75.
16. Rushworth et al. In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer. Life Sci Alliance. 2020;3(2):e202000770.
17. Salji MJ (2018) Quantitative proteomics and metabolomics of castration resistant prostate cancer. Ph.D. thesis, University of Glasgow.
18. Scarsbrook AF, et al. Effect of (18)F-Fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON trial. Int J Radiat Oncol Biol Phys. 2020;107(2):316–24.
19. Nanni C et al. 2014. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer. 12(2):106–10.
20. Pernthaler B, et al. 2019. A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET/CT Clin Nucl Med. 44(10):e566–73.
21. Schwarzenbock S, Souvatzooglou M, Krause BJ. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics. 2012;2(3):318–30.
22. Nanni C, et al. 2016. (18)F-FACBC (anti-1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging 43(9):1601–10.
23. Nanni C, et al. (2015) 18F-fluciclovine PET/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET/CT. Clin Nucl Med. 40(8):e386–391.
24. Schiavina R, et al. 2014. First case of 18F-FACBC PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer and negative 11C-choline PET/CT: new imaging techniques may expand pioneering approaches. Urol Int. 92(2):242–5.
25. Okudaira H, et al. Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. Mol Imaging Biol. 2014;16(6):756–64.
26. Ono M, et al. (14)CFluciclovine (alias anti-14C[F]FACBC) uptake and ASC72 expression in castration-resistant prostate cancer cells. Nucl Med Biol. 2015;42(11):887–92.
27. Wang Q, et al. Targeting ASC72-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol. 2015;236(3):278–89.
28. Wang Q, et al. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res. 2011;71(24):7525–36.